Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Herbalife Nutrition Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Herbalife Nutrition Ltd trades at $12.54 (market cap $1.27B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 6.3× Herbalife Nutrition Ltd's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals.
| BIO | HLF | |
|---|---|---|
Market Cap | $8.04B | $1.27B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $19.96 |
52-Week Low | $241.71 | $7.75 |
Enterprise Value | $7.85B | $3.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Herbalife (HLF) trades at $13.10, down 0.38% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 77.78% gross margin and attractive valuation metrics including a P/E of 5.75 and P/S of 0.27. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, while the company completed a $1.45 billion debt refinancing in April 2026 to strengthen its balance sheet.
The outlook remains positive with analyst consensus favoring Buy ratings (57.69%) and improving debt-to-asset ratios from 82.84% in 2024 to 71.67% in 2025. Key risks include high leverage, competitive pressures in the nutrition space, and regional market volatility. The stock offers value appeal given low multiples and recent strategic initiatives to expand digital health offerings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
